MIA PaCa-2-hCLDN18.2

Export PDF

Strain Information

Validation Data

Ⅰ.In vitro Expression of MIA Paca-2-hCLDN18.2 cell line

image.png

Figure 1. hCLDN18.2 expression in MIA Paca-2 and MIA Paca-2-hCLDN18.2 cell lines

Ⅱ.Characterization of in vivo growth kinetics

Cells were subcutaneously inoculated into the NMG mice.

image.png

Figure 2. Tumor growth curve of MIA Paca-2-hCLDN18.2 xenograft model model (n=5)

image.png

Figure 3. Body weight change of MIA Paca-2-hCLDN18.2 xenograft model model (n=5)

Ⅲ.Expression of hCLDN18.2 protein in tumors

To verify the hCLDN18.2 protein expression, the tumors were dissected and separated for single cell suspension.

image.png

Figure 4. The expression of hCLDN18.2 in humanized modified tumors by FACS



You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more